Posted by Michael Wonder on 22 Jun 2023
Cidara Therapeutics receives US FDA fast track designation for CD388, a novel drug-FC conjugate targeting influenza A and B
22 June 2023 - Cidara Therapeutics today announced that the US FDA has granted fast track designation to CD388, Cidara’s novel drug-Fc conjugate candidate.
CD388 is being developed in collaboration with Janssen Pharmaceuticals for the prevention of influenza A and B infection in adults who are at high risk of severe influenza, including those for whom vaccines are either ineffective or contra-indicated.
